12 hours Ago By Defense World Staff
Miramar Capital LLC bought a new position in shares of Johnson & Johnson ( NYSE:JNJ – Free Report ) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,765 shares of the company’s stock, valued at approximately $258,000. Other hedge funds also recently added to or reduced their stakes in the company.
Meridian Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $1,626,000. Summit Financial Wealth Advisors LLC lifted its position in Johnson & Johnson by 26.3% in the first quarter.
Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock valued at $853,000 after acquiring an additional 1,122 shares during the last quarter. Gilbert & Cook Inc. boosted its stake in Johnson & Johnson by 3.
3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after acquiring an additional 288 shares in the last quarter.
Franklin Parlapiano Turner & Welch LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock worth $7,464,000 after purchasing an additional 325 shares during the last quarter.
Finally, Capital Asset Advisory Services LLC increased its position in shares of Johnson & Johnson by 8.8% during the first quarter. Capital Asset Advisory Services LLC now owns 26,539 shares of the company’s stock worth $4,044,000 after purchasing an additional 2,151 shares in the last quarter.
69.55% of the stock is currently owned by hedge funds and other institutional investors. Insider Buying and Selling at Johnson & Johnson In other news, VP Robert J.
Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.
10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38.
The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . 0.16% of the stock is owned by corporate insiders.
Johnson & Johnson Stock Down 0.5 % Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.
82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11.
The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion.
Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%.
The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.
80 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend.
This represents a $4.96 annualized dividend and a yield of 2.98%.
The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.
Analysts Set New Price Targets JNJ has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday.
TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th.
Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.
00 in a report on Thursday, July 18th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.
00 in a research note on Tuesday, July 23rd. Finally, The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.
00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.
com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.21. Read Our Latest Research Report on JNJ Johnson & Johnson Company Profile ( Free Report ) Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Featured Stories Five stocks we like better than Johnson & Johnson What is a Bond Market Holiday? How to Invest and Trade How Much Can You Make in Stocks in One Month? Industrial Products Stocks Investing This Is the Top Large-Cap Stock Insiders Are Buying How to Effectively Use the MarketBeat Ratings Screener Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter ..
